Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
ESC Heart Fail. 2022 Aug;9(4):2464-2473. doi: 10.1002/ehf2.13943. Epub 2022 Apr 19.
Patients with advanced heart failure (HF) frequently suffer from renal insufficiency. The impact of durable mechanical circulatory support (MCS) and subsequent heart transplantation (HTx) on kidney function is not well described.
We studied patients with advanced HF who received durable MCS as bridge to transplantation (BTT) and underwent subsequent HTx at our centre between 1996 and 2018. Glomerular filtration rate (GFR) was measured by Cr-EDTA or iohexol clearance during heart failure work-up; 3-6 months after MCS; and 1 year after HTx. Chronic kidney disease (CKD) was classified according to KDIGO criteria based on estimated GFR. A total of 88 patients (46 ± 15 years, 84% male) were included, 63% with non-ischaemic heart disease. The median duration of MCS-treatment was 172 (IQR 116-311) days, and 81 subjects were alive 1 year after HTx. Measured GFR increased from 54 ± 19 during HF work-up to 60 ± 16 mL/min/1.73 m after MCS (P < 0.001) and displayed a slight but nonsignificant decrease to 57 ± 22 mL/min/1.73 m 1 year after HTx (P = 0.38). The trajectory of measured GFR did not differ between pulsatile and continuous flow (CF) pumps. Among patients 35-49 years and those who were treated in the most recent era (2012-2018), measured GFR increased following MCS implantation and subsequent HTx. Estimated GFR displayed a similar course as did measured GFR.
In patients with advanced heart failure, measured GFR improved after MCS with no difference between pulsatile and CF-pumps. The total study group showed no further increase in GFR following HTx, but in certain subgroups, including patients aged 35-54 years and those treated during the latest era (2012-2018), renal function appeared to improve after transplant.
患有晚期心力衰竭(HF)的患者常伴有肾功能不全。持久的机械循环支持(MCS)和随后的心脏移植(HTx)对肾功能的影响尚未得到很好的描述。
我们研究了 1996 年至 2018 年间在我们中心接受持久的 MCS 桥接移植(BTT)并随后接受 HTx 的晚期 HF 患者。在心力衰竭检查期间通过 Cr-EDTA 或 iohexol 清除率测量肾小球滤过率(GFR);在 MCS 后 3-6 个月;并在 HTx 后 1 年。根据估计的 GFR,根据 KDIGO 标准将慢性肾脏病(CKD)分类。共纳入 88 例患者(46±15 岁,84%为男性),其中 63%患有非缺血性心脏病。MCS 治疗的中位时间为 172(IQR 116-311)天,81 例患者在 HTx 后 1 年存活。测量的 GFR 从心力衰竭检查时的 54±19 增加到 MCS 后的 60±16 mL/min/1.73 m(P<0.001),并且在 HTx 后 1 年时略有但无统计学意义的降低至 57±22 mL/min/1.73 m(P=0.38)。搏动性和连续流(CF)泵之间测量的 GFR 轨迹没有差异。在 35-49 岁的患者和最近治疗时期(2012-2018 年)的患者中,MCS 植入和随后的 HTx 后测量的 GFR 增加。估计的 GFR 表现出与测量的 GFR 相似的过程。
在晚期心力衰竭患者中,MCS 后测量的 GFR 改善,搏动性和 CF 泵之间没有差异。整个研究组在 HTx 后 GFR 没有进一步增加,但在某些亚组中,包括 35-54 岁的患者和接受最新治疗时期(2012-2018 年)治疗的患者,移植后肾功能似乎有所改善。